Patients without a pretreatment liquid biopsy (N = 32) and patients carrying a tumor with a KRAS mutation that could not be detected by the ddPCR kits (N = 2) were excluded, leaving 122 ctDNA samples for liquid biopsy analyses (Data Supplement Figure 1). The gene discussed is KRAS; the disease is neoplasm.